Impact of CYP2D6 Polymorphism on Equilibrium Concentration of Fluoxetine in Patients Diagnosed With Major Depressive Disorder and Comorbid Alcohol Use Disorders

We examined associations between common psychiatric disorders and fecundity in a population-based cohort of 1,252 twins prospectively assessed from adolescence into adulthood. Major depressive disorder, anxiety disorders, and alcohol use disorders were associated with lower likelihood of having children and having fewer children. Survival analyses yielded similar results accounting for timing and recurrence. Although both early- and adult-onset psychiatric disorders were associated with decreased fecundity, early-onset major depressive disorder, anxiety disorders (among boys), and alcohol use disorders (among girls) were associated with greater likelihood of having a child during adolescence. Among twin pairs discordant for psychiatric disorders (i.e., one twin affected and one twin unaffected by major depressive disorder, anxiety disorders, or alcohol use disorders), twins affected by anxiety and alcohol use disorders but not major depressive disorder were less likely to have children than their unaffected co-twins. However, unaffected twins with an affected co-twin were no more likely to have children than twins from unaffected twin pairs, inconsistent with the balancing-selection hypothesis that increased fecundity in unaffected relatives accounts for persistence of psychiatric disorders.

Download Full-text

Influence of comorbid alcohol use disorders on the clinical patterns of major depressive disorder: A general population-based study

Drug and Alcohol Dependence ◽

10.1016/j.drugalcdep.2018.02.009 ◽

2018 ◽

Vol 187 ◽

pp. 40-47 ◽

Cited By ~ 20

Author(s):

Louise Carton ◽

Baptiste Pignon ◽

Alexandre Baguet ◽

Imane Benradia ◽

Jean-Luc Roelandt ◽

...

Keyword(s):

Major Depressive Disorder ◽

Alcohol Use ◽

General Population ◽

Depressive Disorder ◽

Alcohol Use Disorders ◽

Population Based ◽

Major Depressive ◽

Population Based Study ◽

Clinical Patterns

Download Full-text

Analysis of Patient-reported Outcomes of Quality of Life and Functioning Before and After Treatment of Major Depressive Disorder Comorbid With Alcohol Use Disorders

Journal of Addiction Medicine ◽

10.1097/adm.0000000000000268 ◽

2017 ◽

Vol 11 (1) ◽

pp. 47-54 ◽

Cited By ~ 3

Author(s):

Itai Danovitch ◽

Alexander Joseph Steiner ◽

Anna Kazdan ◽

Matthew Goldenberg ◽

Margaret Haglund ◽

...

Keyword(s):

Quality Of Life ◽

Major Depressive Disorder ◽

Alcohol Use ◽

Depressive Disorder ◽

Patient Reported Outcomes ◽

Alcohol Use Disorders ◽

Major Depressive ◽

Patient Reported ◽

Before And After

Download Full-text

Repetitive Transcranial Magnetic Stimulation for Comorbid Major Depressive Disorder and Alcohol Use Disorder

Brain Sciences ◽

10.3390/brainsci12010048 ◽

2021 ◽

Vol 12 (1) ◽

pp. 48

Author(s):

Victor M. Tang ◽

Bernard Le Foll ◽

Daniel M. Blumberger ◽

Daphne Voineskos

Keyword(s):

Major Depressive Disorder ◽

Transcranial Magnetic Stimulation ◽

Alcohol Use ◽

Depressive Disorder ◽

Magnetic Stimulation ◽

Alcohol Use Disorder ◽

Repetitive Transcranial Magnetic Stimulation ◽

Executive Dysfunction ◽

Common Symptom ◽

Major Depressive

Major depressive disorder (MDD) and alcohol use disorder (AUD) are leading causes of disability, and patients are frequently affected by both conditions. This comorbidity is known to confer worse outcomes and greater illness severity. Repetitive transcranial magnetic stimulation (rTMS) is a non-invasive neuromodulation method that has demonstrated antidepressant effects. However, the study of rTMS for patients with MDD and commonly associated comorbidities, such as AUD, has been largely overlooked, despite significant overlap in clinical presentation and neurobiological mechanisms. This narrative review aims to highlight the interrelated aspects of the literature on rTMS for MDD and rTMS for AUD. First, we summarize the available evidence on the effectiveness of rTMS for each condition, both most studied through stimulation of the dorsolateral prefrontal cortex (DLPFC). Second, we describe common symptom constructs that can be modulated by rTMS, such as executive dysfunction, that are transdiagnostic across these disorders. Lastly, we describe promising approaches in the personalization and optimization of rTMS that may be applicable to both AUD and MDD. By bridging the gap between research efforts in MDD and AUD, rTMS is well positioned to be developed as a treatment for the many patients who have both conditions concurrently.

Download Full-text

Characteristics of Neuropsychiatric Mobile Health Trials: Cross-Sectional Analysis of Studies Registered on ClinicalTrials.gov

JMIR mhealth and uhealth ◽

10.2196/16180 ◽

2020 ◽

Vol 8 (8) ◽

pp. e16180

Author(s):

Mia Tova Minen ◽

Julia Frederica Reichel ◽

Pallavi Pemmireddy ◽

Elizabeth Loder ◽

John Torous

Keyword(s):

Substance Use ◽

Major Depressive Disorder ◽

Alzheimer Disease ◽

Depressive Disorder ◽

Alcohol Use Disorders ◽

Opioid Use ◽

Major Depressive ◽

High Burden ◽

Opioid Use Disorders ◽

Neuropsychiatric Conditions

Background The development of mobile health (mHealth) technologies is progressing at a faster pace than that of the science to evaluate their validity and efficacy. Under the International Committee of Journal Medical Editors (ICMJE) guidelines, clinical trials that prospectively assign people to interventions should be registered with a database before the initiation of the study. Objective The aim of this study was to better understand the smartphone mHealth trials for high-burden neuropsychiatric conditions registered on ClinicalTrials.gov through November 2018, including the number, types, and characteristics of the studies being conducted; the frequency and timing of any outcome changes; and the reporting of results. Methods We conducted a systematic search of ClinicalTrials.gov for the top 10 most disabling neuropsychiatric conditions and prespecified terms related to mHealth. According to the 2016 World Health Organization Global Burden of Disease Study, the top 10 most disabling neuropsychiatric conditions are (1) stroke, (2) migraine, (3) major depressive disorder, (4) Alzheimer disease and other dementias, (5) anxiety disorders, (6) alcohol use disorders, (7) opioid use disorders, (8) epilepsy, (9) schizophrenia, and (10) other mental and substance use disorders. There were no date, location, or status restrictions. Results Our search identified 135 studies. A total of 28.9% (39/135) of studies evaluated interventions for major depressive disorder, 14.1% (19/135) of studies evaluated interventions for alcohol use disorders, 12.6% (17/135) of studies evaluated interventions for stroke, 11.1% (15/135) of studies evaluated interventions for schizophrenia, 8.1% (11/135) of studies evaluated interventions for anxiety disorders, 8.1% (11/135) of studies evaluated interventions for other mental and substance use disorders, 7.4% (10/135) of studies evaluated interventions for opioid use disorders, 3.7% (5/135) of studies evaluated interventions for Alzheimer disease or other dementias, 3.0% (4/135) of studies evaluated interventions for epilepsy, and 3.0% (4/135) of studies evaluated interventions for migraine. The studies were first registered in 2008; more than half of the studies were registered from 2016 to 2018. A total of 18.5% (25/135) of trials had results reported in some publicly accessible location. Across all the studies, the mean estimated enrollment (reported by the study) was 1078, although the median was only 100. In addition, across all the studies, the actual reported enrollment was lower, with a mean of 249 and a median of 80. Only about a quarter of the studies (35/135, 25.9%) were funded by the National Institutes of Health. Conclusions Despite the increasing use of health-based technologies, this analysis of ClinicalTrials.gov suggests that only a few apps for high-burden neuropsychiatric conditions are being clinically evaluated in trials.

Download Full-text